Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanfacine Hydrochloride (TAK-503) in Children and Adolescents With ADHD
NCT04085172Phase 4Completed
- Sponsor
- Takeda
- Start
- Sep 2019
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 4 trial of guanfacine in attention deficit hyperactivity disorder (ADHD), sponsored by Takeda. Started Sep 2019; status: completed.
02
Drugs
guanfacine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT04085172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04085172.